Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NEK2 | P51955 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32687166 | 0.89 | SMN1; SMN2 (0.30) | — | |
| Trifluoroacetic Acid SCHEMBL17319053 | 0.87 | HRH4 (0.31) | — | |
| SCHEMBL11219430 | 0.78 | — | — | |
| SCHEMBL16015716 | 0.77 | — | — | |
| SCHEMBL23243777 | 0.74 | OPRM1 (0.32) | — | |
| SCHEMBL11225549 | 0.74 | — | — | |
| Hydrochloric Acid SCHEMBL12492172 | 0.70 | OPRD1 (0.41) | — | |
| SCHEMBL11225842 | 0.69 | OPRM1 (0.51) | — | |
| SCHEMBL11286317 | 0.68 | MEN1 (0.39) | — | |
| SCHEMBL11229340 | 0.68 | NEK2 (0.32) | NEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11236110-B2 | Salts of (R)-9-(2,5-difluorophenethyl)-4-ethyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2022-02-01 | — | — | US | disclosed |
| WO-2021018824-A1 | USE OF (R)-9-(2,5-DIFLUOROPHENETHYL)-4-ETHYL-2-METHYL-1-OXA-4,9-DIAZASPIRO[5.5]UNDECAN-3-ONE FOR THE TREATMENT OF NOCICEPTIVE PAIN, NEUROPATHIC PAIN, OSTEOARTHRITIS PAIN AND CANCER PAIN, WHILE HAVING REDUCED SIDE EFFECTS COMPARED TO OPIOIDS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2021-02-04 | — | — | WO | disclosed |
| US-20200331929-A1 | SALTS OF (R)-9-(2,5-DIFLUOROPHENETHYL)-4-ETHYL-2-METHYL-1-OXA-4,9-DIAZASPIRO[5.5]UNDECAN-3-ONE | ACONDICIONAMIENTO TARRASENSE (ES) | 2020-10-22 | — | — | US | disclosed |
| EP-3452475-A1 | TETRAHYDROPYRIMIDODIAZEPINE AND TETRAHYDROPYRIDODIAZEPINE COMPOUNDS FOR TREATING PAIN AND PAIN RELATED CONDITIONS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-03-13 | — | — | EP | disclosed |
| WO-2017191304-A1 | TETRAHYDROPYRIMIDODIAZEPINE AND TETRAHYDROPYRIDODIAZEPINE COMPOUNDS FOR TREATING PAIN AND PAIN RELATED CONDITIONS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-11-09 | — | — | WO | disclosed |
| US-4353901-A | HYPERTENSION, CONGESTIVE HEART FAILURE, ARRHYTHMIAMIGRAINE, VASOSPASTIC DISORDERS, ASTHMA | SYNTEX (U.S.A.) INC. (US) | 1982-10-12 | — | — | US | disclosed |
| US-4353900-A | HYPOTENSIVE, ANTIARRHYTHMIA, CARDIOTONIC, VASODILATORS | SYNTEX (U.S.A.) INC. (US) | 1982-10-12 | — | — | US | disclosed |
| EP-0061333-A1 | 9-(2-(3-Indolyl)ethyl)-1-oxa-4,9-diazaspiro(5.5)undecan-3-ones | SYNTEX (U.S.A.) INC. (US) | 1982-09-29 | — | — | EP | disclosed |
| US-4332804-A | TREATMENT OF HYPERTENSION, CONGESTIVE HEART FAILURE, ARRHYTHMIA, MIGRAINE, VASOSPASTIC DISORDERS AND ASTHMA | SYNTEX (U.S.A.) INC. (US) | 1982-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331929-A1 | SALTS OF (R)-9-(2,5-DIFLUOROPHENETHYL)-4-ETHYL-2-METHYL-1-OXA-4,9-DIAZASPIRO[5.5]UNDECAN-3-ONE | OPRM1, OPRD1, OPRK1 | NEK2 4317/4885 |
| US-11236110-B2 | Salts of (R)-9-(2,5-difluorophenethyl)-4-ethyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one | OPRM1, OPRD1, OPRK1 | NEK2 4317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.